CHINA DIABETES DEVICES MARKET - GROWTH, TRENDS, COVID-19 IMPACT, AND FORECASTS (2022 - 2027)

CHINA DIABETES DEVICES MARKET - GROWTH, TRENDS, COVID-19 IMPACT, AND FORECASTS (2022 - 2027)

The China Diabetes Devices Market is expected to register a CAGR greater than 4% over the forecast period, 2022-2027.

According to WHO in January 2020 COVID -19 deaths, there are 20% of people with diabetes and diabetes-related diseases happened in China. Nearly one in ten COVID-19 patients have diabetes in China. Diabetes is associated with a higher risk of severe illness and death. The present study suggested that targeted early intervention is needed in COVID-19 patients with diabetes. According to a study conducted by Peking University, (Beijing China) the intensive care unit (ICU) cases had a roughly three-fold greater frequency of diabetes than non-ICU individuals. Various research produced different findings about the prevalence of diabetes. Almost 60% of those with diabetes experienced food or medication shortages during the quarantine period, which was much higher than those without diabetes. Importantly, respondents who experienced medication shortages reported a 63% higher COVID-19 infection rate.

In 2021, Type 1 diabetes patients accounted for 9.84% of the total diabetes population in China. In China, due to lifestyle and food habits, blood glucose fluctuations among insulin users are frequent from time to time, and self-monitoring of blood glucose fails to accurately reflect the blood glucose profile because it only represents the glucose concentration at a specific time point. Thus, a trend has been observed in the demand for the Diabetes Devices in China.

Key Market TrendsMonitoring Devices Market is growing with the highest CAGR

Patients with type 1 diabetes (T1D) must maintain healthy lifestyle conditions, which are impacted by the combination of a person's personality traits, social interactions, socioeconomic circumstances, and environmental living factors. The use of continuous glucose monitoring (CGM) with multiple daily injections (MDI) has shown a reduction in nonsevere and severe hypoglycemia in people with T1D prone to this adverse event. Patients with T1D who are at a high risk of hypoglycemia may control their blood sugar levels even amid the harsh living circumstances imposed by the COVID-19 pandemic crisis' severe lockdown thanks to the use of standalone continuous glucose monitoring. A little improvement in glucometric markers, particularly those connected to glucose exposure, was linked to the lockdown time. The Spanish hospitals are ordering CGM devices to limit staff contact with a large portion of diabetic patients infected with COVID-19.

Treatment for viral infections in diabetic people might be challenging because of BG level variations. With RT-CGM, it is possible to monitor BG trends and stop drastic fluctuations in glucose levels before they cause problems. The Dexcom G4 Platinum CGM system's ability to monitor from up to 6.0 m reduced the requirement for medical personnel to enter the isolation room. These factors driving the Monitoring Devices Market in China.

Increasing Type -1 Diabetes Population in China

According to estimates, 1 in 10 Chinese citizens in the country have diabetes. During the 21st Century, millions of new cases of diabetes are occurring each year However, a precise statistic for diabetes in China is difficult to calculate because many cases are considered to remain undetected. China is considered to have surpassed India as the country with the greatest diabetes population in the world. Diabetes is most prevalent in China's cities, where economic growth is accelerating and traditional dietary patterns are rapidly eroding. According to China health experts, the key causes of this diabetes number spike include urbanization, improving living standards, and an aging population. According to the National Health Commission, China has made steps to reduce diabetic and high blood pressure patients' medical expenses by reimbursing outpatients for more than half of their medication costs (NHC). According to a national metabolic disease clinical research center, more hospitals in China will establish National Metabolic Management Centers (MMC) as part of their exploration of a new model of diabetes treatment. According to the National Health Commission, China Statistics, MMCs across the country have provided services for more than 200,000 patients over the last two years.

As a result, the diabetes care market in China is predicted to expand gradually in the coming years.

Competitive Landscape

The new technologies in diabetes devices, like continuous glucose monitoring, increased the market for monitoring devices. The mergers and acquisitions between the players, like the acquisition of TypeZero Technologies by Dexcom, are paving the way for automated insulin delivery. The acquisition has sent Dexcom ahead on its way in the race to create an artificial pancreas system, rather than merely offering a boost to the continuous glucose monitoring devices market.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

Please note: This publisher does offer titles that are created upon receipt of order. If you are purchasing a PDF Email Delivery option above, the report will take approximately 2 business days to prepare and deliver.